Progress to Date in A3: Method Transfer, Partial Validation and Cross validation

Size: px
Start display at page:

Download "Progress to Date in A3: Method Transfer, Partial Validation and Cross validation"

Transcription

1 Progress to Date in A3: Method Transfer, Partial Validation and Cross validation

2 A3: Method Transfer, partial and cross validation Team members: Team lead Ray Briggs EU Other members Richard Abbott-EU Margarete Brudny-Kloeppel -EU Patrick Duchene-EU Jan Busch-NA Bob Nicholson NA Naidong Weng-NA Faye Vazvaei-NA Mahesh Kumar-APAC Masanari Mabuchi-APAC Paulo Galvinas-LA Pei Hu (APAC) Interdependencies with other teams if any L1 Ligand Binding Run Acceptance S1 Small Molecule Run Acceptance A2 Tiered Approach for method validation A6 Stability A7 Repeat Analysis and ISR In scope Life cycle of a method after first full validation or relation with other validated methods. Partial validation Method transfer Cross validation Definitions of method transfer, partial and cross validations Recommendation on when to perform method transfer, partial and cross validations Specific requirements for the transfer, partial validation and cross validation of small and large molecules Recommendations of which experiments are desirable for each proposed steps after full validation Recommendations of acceptance criteria for cross validations and method transfers Use of quality control material and incurred samples for transfer, partial validation and cross validation Pre assessment activities in method transfer and their importance to successful transfer Out of scope Scope will be limited to PK analyses only at this 5me 2

3 Method Validation Life Cycle Development Method Feasibility Full Validation Partial Validation Initial Method Revised Method New Species Method Transfer Internal/External Issue/Investigation Cross Validation Another Method/ Lab

4 Perspectives There is considerable overlap in the terminology and definition of method, transfer, partial validation and cross validation The life cycle of a bioanalytical method can be complex which adds to the confusion Current Regulatory Guidance in these areas is minimal The A3 team s primary objective was to introduce clarity into the terminology and to reduce overlaps between the concepts as far as is possible, while avoiding being prescriptive.

5 Method Transfer A specific activity which allows implementation of an existing analytical method in another laboratory. Level of method validation dependant on whether the receiving laboratory can be considered internal (working with the same SOPs and facilities as the initiating laboratory) or as an external laboratory May include use of spiked QCs to determine equivalence of methods

6 Method Transfer Requirements Internal Transfers 2 accuracy and precision batches (4 for ligand binding) External Transfers (or where critical reagents are not shared ) Full validation Inter-laboratory Comparison The objective is to demonstrate that the transferred method performs as originally validated

7 Partial Validation The demonstration of assay reliability following a minor modification of an existing bioanalytical method that has been fully validated previously. The nature of the modification will determine the extent of validation required. Level of validation will depend on the nature and extent of the method change (example will be provided including acceptance criteria)

8 Partial Validation Requirements What should be included will vary according to the nature of the method change required Experiments required will normally have acceptance criteria in line with full validation requirements Matrix stability will not need to be repeated as part of partial validation The team is preparing an example of the types of experiments that should be considered in each case but recognizes that it would be difficult to be prescriptive

9 Cross Validation A comparison of data obtained from at least 2 different laboratories or within and across studies with at least 2 different validated analytical methods to determine whether the obtained data are reliable and comparable. Cross validation consists of analysis of assessment samples, (spiked QCs and incurred samples) assayed using both validated methods, as appropriate.

10 Further Ongoing Discussions To identify the general requirements for acceptance criteria to be employed in each case To agree to the necessity and scope of employing incurred samples in these experiments To determine the variance between current practise and current guidance To discuss any regional variations in current practise.

AAPS/PSCW 2010 APQ Open Forum

AAPS/PSCW 2010 APQ Open Forum AAPS/PSCW 2010 APQ Open Forum Harmonization of Global Bioanalytical Regulations Scientific Perspective and Update on Developments 18 November 2010 Steve Lowes, Ph.D. Advion BioServices Inc Ithaca, NY Introduction

More information

Current Developments in Guidance for Regulatory Bioanalysis

Current Developments in Guidance for Regulatory Bioanalysis Current Developments in Guidance for Regulatory Bioanalysis Dr Gerry McGuire Resolution Analytical Consultancy Ltd Edinburgh, Scotland UK gerry@resolutioneurope.com 1st MENA Regulatory Conference on Bioequivalence,

More information

GLOBAL BIOANALYSIS CONSORTIUM

GLOBAL BIOANALYSIS CONSORTIUM GLOBAL BIOANALYSIS CONSORTIUM Regulated Bioanalysis - A Proposed Global Harmonization Process Presented by Peter van Amsterdam for GBC SoFAQ International Seminar "Quality Assurance and Electronic Data"

More information

Assay Cross Validation

Assay Cross Validation Assay Cross Validation Recent experiences in transferring bioanalytical assays from sponsor to CRO partners and between CROs Stephen White EBF Open Symposium Barcelona 20 th Nov 2013 Assay Cross Validation

More information

GLOBAL BIOANALYSIS CONSORTIUM

GLOBAL BIOANALYSIS CONSORTIUM GLOBAL BIOANALYSIS CONSORTIUM Scope and Regulations Harmonization Team: A1 (Work in Progress) John Smeraglia on behalf of the HT-A1 A1: Scope and regulations Team members: Team lead Region Expertise Surendra

More information

AAPS Views on Bioanalytical Method Validation Harmonization (on Behalf of AAPS Bioanalytical Community)

AAPS Views on Bioanalytical Method Validation Harmonization (on Behalf of AAPS Bioanalytical Community) AAPS Views on Bioanalytical Method Validation Harmonization (on Behalf of AAPS Bioanalytical Community) Faye Vazvaei, Roche Innovation Center New York The 8th JBF Meeting, 8-9 February 2017 Background

More information

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory SQA National Meeting 29Mar2017 Carolyn Eberhardt, Principal Consultant, QC2 Mark Stiles, Senior Consultant, QC2 Comparison of Quality

More information

4/10/2017. Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

4/10/2017. Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory SQA National Meeting 29Mar2017 Carolyn Eberhardt, Principal Consultant, QC2 Mark Stiles, Senior Consultant, QC2 Comparison of Quality

More information

Bioanalytical Method Development and Validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry

Bioanalytical Method Development and Validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry Journal of Applied Bioanalysis http://dx.doi.org/10.17145/jab.18.010 COMMENTARY Bioanalytical Method Development and Validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry Roland J.W.

More information

GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON THE CONDUCT OF GCP INSPECTIONS BY COMPETENT AUTHORITIES OF THE DIFFERENT MEMBER STATES

GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON THE CONDUCT OF GCP INSPECTIONS BY COMPETENT AUTHORITIES OF THE DIFFERENT MEMBER STATES EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 5 November 2008 ENTR/F/2/SF D(2008) 34957 GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON

More information

Update on ANVISA Bioanalytical Method Validation (BMV) Guideline

Update on ANVISA Bioanalytical Method Validation (BMV) Guideline Av. Andrade Neves, 295 - Sala 184 - Ed. Torre São Paulo - Centro - Campinas/SP CEP: 13013-160 - F:(+55-19)3231 8146 acbio@acbio.org.br - www.acbio.org.br Update on ANVISA Bioanalytical Method Validation

More information

Regulated bioanalysis status in Japan and notable points of the draft Japanese guideline

Regulated bioanalysis status in Japan and notable points of the draft Japanese guideline Regulated bioanalysis status in Japan and notable points of the draft Japanese guideline EBF 5th Open Meeting Old Battles, New Horizons, November, 16, 2012, Barcelona Noriko Katori, PhD National Institute

More information

White Paper. For reprint orders, please contact

White Paper. For reprint orders, please contact White Paper For reprint orders, please contact reprints@future-science.com The European Bioanalysis Forum community s evaluation, interpretation and implementation of the European Medicines Agency guideline

More information

GLOBAL BIOANALYSIS CONSORTIUM

GLOBAL BIOANALYSIS CONSORTIUM GLOBAL BIOANALYSIS CONSORTIUM Regulated Bioanalysis - A Proposed Global HarmonizaDon Process presented by Peter Van Amsterdam on behalf of GBC at 3 rd EBF Focus Mee=ng June 13 th 2012 - Brussels - BELGIUM

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 21 September 2006 EMEA/CHMP/BWP/298390/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON

More information

Bioanalytical Issues when. Brigitte Pellerin Bioanalytical Associate Director

Bioanalytical Issues when. Brigitte Pellerin Bioanalytical Associate Director Bioanalytical Issues when Dealing with Phase II/III Studies Brigitte Pellerin Bioanalytical Associate Director 17-NOV-2015 Agenda Different phases of clinical trials Phase I to IV Challenges with Phase

More information

Hemostasis Test Validation, Performance and Reference Intervals

Hemostasis Test Validation, Performance and Reference Intervals Hemostasis Test Validation, Performance and Reference Intervals Richard A. Marlar, Ph.D. Pathology and Laboratory Medicine Oklahoma City VA Medical Center University of Oklahoma Health Sciences Center

More information

The regulatory landscape Stephen White on behalf of the EBF

The regulatory landscape Stephen White on behalf of the EBF The regulatory landscape Stephen White on behalf of the EBF http://www.europeanbioanalysisforum.eu Overview 1. MIST and DDI Guideline 2. Regulatory landscape for BA 3. Tiered Approach on BA of metabolites

More information

Bioequivalence Requirements: USA and EU

Bioequivalence Requirements: USA and EU Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,

More information

Updates on the Progress of the. Harmonization Teams (GBC-HT) for Small & Large Molecules

Updates on the Progress of the. Harmonization Teams (GBC-HT) for Small & Large Molecules Updates on the Progress of the Global BioanalyticalConsortium Harmonization Teams (GBC-HT) for Small & Large Molecules Dr. Fabio Garofolo for GBC AAPS Annual Meeting October 2011 - Washington DC -USA Agenda

More information

Microscopy Studies. Evaluation Study design

Microscopy Studies. Evaluation Study design Ensuring quality in diagnostic trials: Microscopy Studies C N Paramasivan Evaluation Study design Evaluation of Clinical Performance*: Sensitivity: Direct & conc. smears in culture pos. cases compared

More information

Case Studies, or Verification Vignettes

Case Studies, or Verification Vignettes Case Studies, or Verification Vignettes 1 Vignette #1 Change from One Automated AST to Another Your lab is changing from one FDA-cleared automated AST to another Is a verification study required? 2 Yes

More information

Evolutionary Outsourcing Model: Delivering Solutions through Partnership. Tammy Harter and Tony Parry Clinical Bioanalysis Alliance (CBioA)

Evolutionary Outsourcing Model: Delivering Solutions through Partnership. Tammy Harter and Tony Parry Clinical Bioanalysis Alliance (CBioA) Evolutionary Outsourcing Model: Delivering Solutions through Partnership Tammy Harter and Tony Parry Clinical Bioanalysis Alliance (CBioA) Introduction Pre Alliance Years History Drivers for change The

More information

It s Just a Waived Glucose, Isn t It?

It s Just a Waived Glucose, Isn t It? It s Just a Waived Glucose, Isn t It? What Is the Next Step? Becky Damiani, MT (ASCP), Senior Inspection Specialist Laboratory Accreditation Program Objectives Understand the CLIA requirements surrounding

More information

Method Development and Validation for Nutraceuticals

Method Development and Validation for Nutraceuticals White Paper Method Development and Validation for Nutraceuticals Maud Silvent Technical Specialist David Neville Technical Specialist Method Development and Validation for Nutraceuticals Introduction Nutraceutical

More information

LC-MS/MS for the quantification of Peptide biomarker and mixture of closely related Protein in formulation

LC-MS/MS for the quantification of Peptide biomarker and mixture of closely related Protein in formulation EUROPEAN BIOANALYSIS FORUM Barcelona, November 14-16, 2012 LC-MS/MS for the quantification of Peptide biomarker and mixture of closely related Protein in formulation Luc-Alain SAVOY CONTENT Part I: SGS

More information

The 6 th JBF Symposium Program (draft) Challenge of Regulated Bioanalysis

The 6 th JBF Symposium Program (draft) Challenge of Regulated Bioanalysis The 6 th JBF Symposium Program (draft) Challenge of Regulated Bioanalysis Date: 25 th -26 th February 2015 Venue: Tower Hall Funabori, Tokyo, Japan (Oral presentation:small Hall on 5F, Poster session :

More information

Innovative method for Vitamin Analysis at point of production

Innovative method for Vitamin Analysis at point of production Innovative method for Vitamin Analysis at point of production Introduction Bringing quality control to the production line Implementing a system for quality control of raw materials and products at the

More information

Developing Bioanalytical Methods Balancing the Statistical Tightrope

Developing Bioanalytical Methods Balancing the Statistical Tightrope Developing Bioanalytical Methods Balancing the Statistical Tightrope Lee: can I use this number? Process Development GSK, 1997 2 it s about 40 about 40? probably... 3 Enlightenment? 5 Unconscious Conscious

More information

The Virtues and Pitfalls of Implementing a New Test

The Virtues and Pitfalls of Implementing a New Test The Virtues and Pitfalls of Implementing a New Test James H. Nichols, Ph.D., DABCC, FACB Professor of Clinical Pathology, Microbiology and Immunology Associate Medical Director for Clinical Operations

More information

CT Quality Control Manual FAQs

CT Quality Control Manual FAQs CT Quality Control Manual FAQs General Question: How often will the QC Manual be updated and how will those updates be communicated? Answer: The ACR CT Physics Subcommittee will review any comments, issues

More information

Challenges in Performing a Scientifically Meaningful Lipemic Plasma Test in Bioanalytical Method Validation

Challenges in Performing a Scientifically Meaningful Lipemic Plasma Test in Bioanalytical Method Validation Challenges in Performing a Scientifically Meaningful Lipemic Plasma Test in Bioanalytical Method Validation Laurence Mayrand-Provencher, Milton Furtado, Jean- Nicholas Mess, Josée Michon, Annik Bergeron,

More information

Measuring Lipid Composition LC-MS/MS

Measuring Lipid Composition LC-MS/MS Project: Measuring Lipid Composition LC-MS/MS Verification of expected lipid composition in nanomedical controlled release systems by liquid chromatography tandem mass spectrometry AUTHORED BY: DATE: Sven

More information

The 6 th JBF Symposium Program Challenge of Regulated Bioanalysis

The 6 th JBF Symposium Program Challenge of Regulated Bioanalysis 25 th February (Wed.) The 6 th JBF Symposium Program Challenge of Regulated Bioanalysis Date: 25 th -26 th February 2015 Venue: Tower Hall Funabori, Tokyo, Japan (Oral presentation:small Hall on 5F, Poster

More information

Performance Guide. icheck Chroma 3 The test kit to measure vitamin A in oil

Performance Guide. icheck Chroma 3 The test kit to measure vitamin A in oil Performance Guide icheck Chroma 3 The test kit to measure vitamin A in oil Performance explained This Performance Guide is intended to explain the validity of our test kit icheck Chroma 3 in a nutshell

More information

Standard Operating Procedures (SOP) Research and Development Office

Standard Operating Procedures (SOP) Research and Development Office Standard Operating Procedures (SOP) Research and Development Office Title of SOP: GCP Inspection Procedures (MHRA) SOP Number: 15 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review

More information

9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience

9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience Judith Creba Head EU Liaison and Policy, DRA Novartis Pharma AG, Switzerland Disclaimer The views

More information

The analytical phase

The analytical phase The analytical phase Result interpretation Test request Result Sampling Black box: the lab ANALYTICAL PHASE The CASE Uncle Pete, 67 years old Marked abdominal pain 8 pm, ED Acute abdomen? Assessment (+

More information

your bioassay is in good hands: transfer from a CRO perspective MIKE MERGES March 4, 2013

your bioassay is in good hands: transfer from a CRO perspective MIKE MERGES March 4, 2013 your bioassay is in good hands: transfer from a CRO perspective MIKE MERGES March 4, 2013 Contact Information Michael Merges, M.S. Director Analytical Development Solutions Development & Clinical Services

More information

INTERNAL QUALITY CONTROL ( Q I C) QC)

INTERNAL QUALITY CONTROL ( Q I C) QC) EXTERNAL QUALITY ASSESSMENT PROGRAM (EQAP) BIOCHEMISTRY DEPARTMENT R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty TWO COMPLEMENTARY COMPONENETS OF TQM ARE Internal Quality Control (IQC)

More information

EBF Tiered approach final. Validation criteria. Philip Timmerman, on behalf of the EBF 8 th EBF Open Symposium

EBF Tiered approach final. Validation criteria. Philip Timmerman, on behalf of the EBF 8 th EBF Open Symposium EBF Tiered approach final recommendation of Scientific Validation criteria Philip Timmerman, on behalf of the EBF 8 th EBF Open Symposium - 2015 The problem statement 1990 CC-I 2001 FDA Further refinement,

More information

Oncology Programme 2015

Oncology Programme 2015 Oncology Programme 2015 Overview This document explains the University of KwaZulu-Natal Medical Scheme Oncology Programme for 2015 It gives you details about: What you need to do when you are diagnosed

More information

Aseptic Process Simulation (APS) Program Risk Assessment

Aseptic Process Simulation (APS) Program Risk Assessment Aseptic Process Simulation (APS) Program Risk Assessment Angie Bragdon and Patrick Henderson Eli Lilly & Company Indianapolis Parenteral Manufacturing Agenda Background Process Case Studies Q&A 2 Background

More information

Vitamin D Metabolite Analysis in Biological Samples Using Agilent Captiva EMR Lipid

Vitamin D Metabolite Analysis in Biological Samples Using Agilent Captiva EMR Lipid Vitamin D Metabolite Analysis in Biological Samples Using Agilent Captiva EMR Lipid Application Note Clinical Research Authors Derick Lucas and Limian Zhao Agilent Technologies, Inc. Abstract Lipids from

More information

Oncology Programme 2017

Oncology Programme 2017 Oncology Programme 2017 Who we are Remedi Medical Aid Scheme (referred to as 'the Scheme"), registration number 1430, is a non-profit organisation, registered with the Council for Medical Schemes. Discovery

More information

Global Spine Market with Focus on Spinal Fusion: Industry Analysis & Outlook ( )

Global Spine Market with Focus on Spinal Fusion: Industry Analysis & Outlook ( ) Industry Research by Koncept Analytics Global Spine Market with Focus on Spinal Fusion: Industry Analysis & Outlook ----------------------------------------- (2016-2020) December 2016 1 Executive Summary

More information

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Final Concept Paper E9(R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials dated 22 October 2014 Endorsed

More information

METHOD VALIDATION CASE

METHOD VALIDATION CASE METHOD VALIDATION CASE METHOD VALIDATION PROTOCOL CLIA Regulation 493.1253 (2) 1.Accuracy (closeness to true/comparative method) 2.Precision (reproducibility) 3.Reference Interval 4.Reportable range (linearity,

More information

Sponsored and reviewed by ICCS Quality and Standards Committee Title: Verification of PNH assay sensitivity through spiking experiment Written by:

Sponsored and reviewed by ICCS Quality and Standards Committee Title: Verification of PNH assay sensitivity through spiking experiment Written by: Sponsored and reviewed by ICCS Quality and Standards Committee Title: Verification of PNH assay sensitivity through spiking experiment Written by: A Illingworth, T Oldaker, R Sutherland, S Kotanchiyev,

More information

New Annex 15 Updated Requirements & Approach to Validation. Presented by Ashley Isbel 10 th August 2015

New Annex 15 Updated Requirements & Approach to Validation. Presented by Ashley Isbel 10 th August 2015 New Annex 15 Updated Requirements & Approach to Validation Presented by Ashley Isbel 10 th August 2015 EU GMP Guide Annex 15 Qualification & Validation 2001 Current version of Annex 15 published Nov 2012

More information

Sample logistics: problems and solutions in multi-center clinical trials Proposed Generic EBF Lab Manual

Sample logistics: problems and solutions in multi-center clinical trials Proposed Generic EBF Lab Manual Sample logistics: problems and solutions in multi-center clinical trials Proposed Generic EBF Lab Manual Rebecca Sleigh on behalf of TT-12 6 th EBF Open Symposium 20-22 November 2013 Hesperia Tower, Barcelona

More information

Introduction On Assessing Agreement With Continuous Measurement

Introduction On Assessing Agreement With Continuous Measurement Introduction On Assessing Agreement With Continuous Measurement Huiman X. Barnhart, Michael Haber, Lawrence I. Lin 1 Introduction In social, behavioral, physical, biological and medical sciences, reliable

More information

Research Article Derivative Spectrophotometric Method for Estimation of Metformin Hydrochloride in Bulk Drug and Dosage Form

Research Article Derivative Spectrophotometric Method for Estimation of Metformin Hydrochloride in Bulk Drug and Dosage Form Research Article Derivative Spectrophotometric Method for Estimation of Metformin Hydrochloride in Bulk Drug and Dosage Form Gowekar NM, Lawande YS*, Jadhav DP, Hase RS and Savita N. Gowekar Department

More information

GUIDANCE FOR THE ACCREDITATION OF GENERIC METHODS & METHODS OF FLEXIBLE SCOPE OF DETERMINATION OF METALS IN FOODS

GUIDANCE FOR THE ACCREDITATION OF GENERIC METHODS & METHODS OF FLEXIBLE SCOPE OF DETERMINATION OF METALS IN FOODS GUIDANCE FOR THE ACCREDITATION OF GENERIC METHODS & METHODS OF FLEXIBLE SCOPE OF DETERMINATION OF METALS IN FOODS ESYD G-METALS/01/01/20-10-2016 1/6 ESYD G-METALS Issue: 01 Revision: 01 Issue Date: 24-10-2008

More information

Global Harmonization Task Force SG3 Comments and Recommendations ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO and 13488

Global Harmonization Task Force SG3 Comments and Recommendations ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO and 13488 Page 1 of 6 Global Harmonization Task Force SG3 ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO 13485 and 13488 GENERAL COMMENTS The Global Harmonization Task Force Study Group Three (GHTF

More information

Performance Guide. icheck Iodine The test kit to measure iodine in salt

Performance Guide. icheck Iodine The test kit to measure iodine in salt Performance Guide icheck Iodine The test kit to measure iodine in salt Performance explained This Performance Guide is intended to explain the validity of our test kit icheck Iodine in a nutshell to facilitate

More information

Guidance for Pharmacists on Safe Supply of Oral Methotrexate

Guidance for Pharmacists on Safe Supply of Oral Methotrexate Guidance for Pharmacists on Safe Supply of Oral Methotrexate Pharmaceutical Society of Ireland Version 2 January 2015 Contents 1. Introduction 2 2. Methotrexate 2 3. Guidance 2 3.1 Patient Review 2 3.2

More information

Guidelines for Investigating & Assessing Product Endotoxin Failures Richard Fitzpatrick & Aoife Brady

Guidelines for Investigating & Assessing Product Endotoxin Failures Richard Fitzpatrick & Aoife Brady Guidelines for Investigating & Assessing Product Endotoxin Failures Richard Fitzpatrick & Aoife Brady 1 Content Summary of Irish Pharmaceutical/Medical Device Industry Background on Endotoxin What are

More information

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop

More information

Overview of Matrix Effects in Bioanalysis

Overview of Matrix Effects in Bioanalysis Overview of Matrix Effects in Bioanalysis Patrick Bennett & Jing Tu PPD Laboratories 31March2017 Outline 1. Definitions 2. Overview of Matrix Effects 3. Regulatory guidance on matrix effect(s): FDA and

More information

Biomarker Assay validation the Gold, Silver, Bronze approach

Biomarker Assay validation the Gold, Silver, Bronze approach the Gold, Silver, Bronze approach Marianne Scheel Fjording (MAFJ) Development Bioanalysis Novo Nordisk A/S European Bioanalysis Forum 20-Nov-2014 Create clarity about intended use of data There is an increased

More information

A118 Laboratory Proficiency Testing Plan Revision 1.4 March 6, 2014

A118 Laboratory Proficiency Testing Plan Revision 1.4 March 6, 2014 Revision 1.4 March 6, 2014 TABLE OF CONTENTS 1.0 INTRODUCTION...1 2.0 IMPLEMENTATION...1 3.0 COMPLETING THE PLAN...1 4.0 MONITORING FOR COMPLIANCE...2 5.0 NEW APPENDICES...3 6.0 QUESTIONS...3 Rev 1.4 LABORATORY

More information

VALIDATION REPORT Ochratoxin A ELISA (According to the Commission Regulation (EU) No 519/2014)

VALIDATION REPORT Ochratoxin A ELISA (According to the Commission Regulation (EU) No 519/2014) VALIDATION REPORT Ochratoxin A ELISA (According to the Commission Regulation (EU) No 519/2014) Beijerinckweg 18 NL-6827 BN Arnhem The Netherlands Phone: +31 26 363 0 364 info@europroxima.com 1. Introduction

More information

IMPORTANT DISCLAIMER. Note

IMPORTANT DISCLAIMER. Note yn EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL June 2012 DRAFT GUIDANCE DOCUMENT FOR COMPETENT AUTHORITIES FOR THE CONTROL OF COMPLIANCE WITH EU LEGISLATION ON: Regulation (EU) No 1169/2011

More information

SUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE

SUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE SUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE COMMENTS FROM Astellas Pharma Europe BV, Elisabethhof 19, 2353EW Leiderdorp, The Netherlands GENERAL COMMENTS A guiding document on the

More information

Ensuring bioanalytical compliance of your BA/BE study

Ensuring bioanalytical compliance of your BA/BE study Ensuring bioanalytical compliance of your BA/BE study Helmut Schütz BEBAC Consultancy Services for Bioequivalence and Bioavailability Studies 1070 Vienna, Austria helmut.schuetz@bebac.at Dissolution, Bioavailability

More information

Drug development of highly potent therapeutic peptides Regulated microdose Bioanalysis

Drug development of highly potent therapeutic peptides Regulated microdose Bioanalysis Drug development of highly potent therapeutic peptides Regulated microdose Bioanalysis Magnus Knutsson, Director, Bioanalysis LC-MS/MS Ferring Pharmaceuticals A/S Copenhagen, Denmark Presented at EBF Open

More information

The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017

The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017 The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017 Jan Willem van der Laan ( EC, Europe, Regulatory Chair), Todd Bourcier (FDA, US), Tania Cavaliero (Swissmedic,

More information

CLINITEK Novus Automated Urine Chemistry Analyzer

CLINITEK Novus Automated Urine Chemistry Analyzer CLINITEK, Atlas, Novus, Status+, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc. or its affiliates. All other trademarks are properties of their respective owners. Product

More information

Ultra-sensitive biomarker quantification in 1µl to 5µl sample volume

Ultra-sensitive biomarker quantification in 1µl to 5µl sample volume Ultra-sensitive biomarker quantification in 1µl to 5µl sample volume Dr. Beena Punnamoottil Sen. Project Manager Chimera Biotec GmbH punnamoottil@chimera-biotec.com Microsampling I t=0 t=1 t=2 t=3 t=4

More information

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products 25 June 2013 rev. 1 1. Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human 1 Editorial revisions have been made to the table of

More information

FIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland

FIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland FIT - A Tale of Two Settings Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland Possible Conflicts of Interest Consultant: Kyowa, Tokyo, Japan Consultant:

More information

Fiona Campbell. ISA 315 (Revised) Responding to Comments to the Exposure Draft. Deputy Chair of the IAASB and Chair of the ISA 315 Task Force

Fiona Campbell. ISA 315 (Revised) Responding to Comments to the Exposure Draft. Deputy Chair of the IAASB and Chair of the ISA 315 Task Force ISA 315 (Revised) Responding to Comments to the Exposure Draft IAASB Meeting March 12 th, 2019 Fiona Campbell Deputy Chair of the IAASB and Chair of the ISA 315 Task Force Responses to ED-315 Broad concerns

More information

Providing a Universal, One-step Alternative to Liquid-Liquid Extraction in Bioanalysis

Providing a Universal, One-step Alternative to Liquid-Liquid Extraction in Bioanalysis Providing a Universal, ne-step Alternative to Liquid-Liquid Extraction in Bioanalysis Jessalynn P. Wheaton, Erin E. Chambers, and Kenneth J. Fountain APPLICATIN BENEFITS n Simple, one-step sample preparation

More information

Allergy Therapeutics Ltd. Comments on:

Allergy Therapeutics Ltd. Comments on: Allergy Therapeutics Ltd. Comments on: Delegated act on the detailed rules for a unique identifier for medicinal products for human use, and its verification Concept paper submitted for public consultation

More information

Standardised Lab Manual for bioanalytical support in clinical studies : Introducing the harmonised Lab Manual. Introduction to the Workshop

Standardised Lab Manual for bioanalytical support in clinical studies : Introducing the harmonised Lab Manual. Introduction to the Workshop Standardised Lab Manual for bioanalytical support in clinical studies : Introducing the harmonised Lab Manual Introduction to the Workshop Philip Timmerman (for EBF) 05 February 2014 NH Sablon Hotel, Brussels

More information

The EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn,

The EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn, The EU PIP - a step in Pediatric Drug Development Thomas Severin Bonn, 13.01.2009 Agenda Implications for Industry Company Preparation Time of PIP Submission Content of the PIP The PIP Process and first

More information

EFSA s perspective on risk assessment of chemical mixtures

EFSA s perspective on risk assessment of chemical mixtures EFSA s perspective on risk assessment of chemical mixtures Christer Hogstrand King s College London Jean-Lou Dorne European Food Safety Authority, Scientific Committee Past Activities on Chemical Mixtures

More information

JBF Annual Report FY2014

JBF Annual Report FY2014 JBF Annual Report FY2014 (From 1 st April 2014 to 31 st March 2015) 1. Overview It has been passed three years and a half since the establishment of Japan Bioanalysis Forum (JBF). We aim to facilitate

More information

Feed Additive Approval An Industry View. Dr Heidi Burrows Regulatory manager

Feed Additive Approval An Industry View. Dr Heidi Burrows Regulatory manager Feed Additive Approval An Industry View Dr Heidi Burrows Regulatory manager Classification of substances and products used in Animal Nutrition Processing Aid (EC No 1831/2003) Veterinary Substance / Products

More information

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 IAASB Main Agenda (March 2005) Page 2005 579 Agenda Item 13-F DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 Introduction This memorandum provides some background to, and

More information

Concept paper on a Guideline for allergen products development in moderate to low-sized study populations

Concept paper on a Guideline for allergen products development in moderate to low-sized study populations 1 2 3 4 5 6 7 13 December 2018 EMA/CHMP/251023/2018 Rheumatology / Immunology Working Party (RIWP) Concept paper on a Guideline for allergen products development in moderate to low-sized study populations

More information

Detection of Cotinine and 3- hydroxycotine in Smokers Urine

Detection of Cotinine and 3- hydroxycotine in Smokers Urine Detection of Cotinine and 3- hydroxycotine in Smokers Urine Behavioural and Situational Research Group School of Medicine, University of Tasmania Version number: 2 Effective date: 01/12/2015 Review due:

More information

Real-time PK Measurement of the Chemotherapeutic Drug Melphalan in Whole Blood by a Novel PaperSpray Mass Spectrometry

Real-time PK Measurement of the Chemotherapeutic Drug Melphalan in Whole Blood by a Novel PaperSpray Mass Spectrometry Palm Springs, California February 21-25 Real-time PK Measurement of the Chemotherapeutic Drug Melphalan in Whole Blood by a Novel PaperSpray Mass Spectrometry Junfang Zhao, Chandra Sharat, Parinda A. Mehta,

More information

Helmut Schütz. Satellite Short Course Budapest, 5 October

Helmut Schütz. Satellite Short Course Budapest, 5 October Multi-Group and Multi-Site Studies. To pool or not to pool? Helmut Schütz Satellite Short Course Budapest, 5 October 2017 1 Group Effect Sometimes subjects are split into two or more groups Reasons Lacking

More information

US FDA Process Validation Guidance. Presented by Marc Fini 21 May, 2013

US FDA Process Validation Guidance. Presented by Marc Fini 21 May, 2013 US FDA Process Validation Guidance Presented by Marc Fini 21 May, 2013 Validation The risk based approach to validation must be used to determine: What to validate When to validate How to validate How

More information

Challenges in environmental risk assessment (ERA) for birds and mammals and link to endocrine disruption (ED) Katharina Ott, BASF SE, Crop Protection

Challenges in environmental risk assessment (ERA) for birds and mammals and link to endocrine disruption (ED) Katharina Ott, BASF SE, Crop Protection Challenges in environmental risk assessment (ERA) for birds and mammals and link to endocrine disruption (ED) Katharina Ott, BASF SE, Crop Protection Charles River Symposium, Den Bosch, 3rd October 2017

More information

FoodDrinkEurope Position on GLP studies

FoodDrinkEurope Position on GLP studies FoodDrinkEurope Position on GLP studies Content of the presentation Introduction to GLP Importance of GLP for the food industry Use of GLP based on the example of novel foods Conclusions GLP what is it?

More information

A Standardized Procedure for the Simultaneous Determination of the Matrix Effect, Recovery, Process Efficiency and Internal Standard Association

A Standardized Procedure for the Simultaneous Determination of the Matrix Effect, Recovery, Process Efficiency and Internal Standard Association Supporting Information A Standardized Procedure for the Simultaneous Determination of the Matrix Effect, Recovery, Process Efficiency and Internal Standard Association Jean-François Bienvenu*, Gilles Provencher,

More information

ESS Method 310.2: Phosphorus, Total, Low Level (Persulfate Digestion)

ESS Method 310.2: Phosphorus, Total, Low Level (Persulfate Digestion) ESS Method 310.2: Phosphorus, Total, Low Level (Persulfate Digestion) Environmental Sciences Section Inorganic Chemistry Unit Wisconsin State Lab of Hygiene 465 Henry Mall Madison, WI 53706 Revised October

More information

Academic Insights for Biomarker Priorities and Candidate Pilot Project(s)

Academic Insights for Biomarker Priorities and Candidate Pilot Project(s) Academic Panel Session Academic Insights for Biomarker Priorities and Candidate Pilot Project(s) Moderators: Dr. Chirag Parikh (Yale) Dr. Kumar Sharma (UCSD) Panelists: Dr. Ronald Perrone (Tufts Medical

More information

NATIONAL PROFILES FOR DENTAL SERVICES & ORAL HEALTH PRACTITIONERS CONTENTS

NATIONAL PROFILES FOR DENTAL SERVICES & ORAL HEALTH PRACTITIONERS CONTENTS NATIONAL PROFILES FOR DENTAL SERVICES & ORAL HEALTH PRACTITIONERS CONTENTS Profile Title AfC Banding Page Dental Technician 5 Oral Health Practitioner 5 Dental Technician Specialist 6 Oral Health Practitioner

More information

The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats - Status Report

The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats - Status Report INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats - Status Report Introduction The ICH

More information

METHOD VALIDATION: WHY, HOW AND WHEN?

METHOD VALIDATION: WHY, HOW AND WHEN? METHOD VALIDATION: WHY, HOW AND WHEN? Linear-Data Plotter a,b s y/x,r Regression Statistics mean SD,CV Distribution Statistics Comparison Plot Histogram Plot SD Calculator Bias SD Diff t Paired t-test

More information

Welcome to the American College of Toxicology s Webinar Series. Implications for Toxicology/Toxicokinetics When ISR Fails

Welcome to the American College of Toxicology s Webinar Series. Implications for Toxicology/Toxicokinetics When ISR Fails Welcome to the American College of Toxicology s Webinar Series Implications for Toxicology/Toxicokinetics When ISR Fails Presenters Elizabeth A. Groeber, Ph.D. Director Bioanalytical Chemistry WIL Research,

More information

Country Participation: An Overview for Interested Investigators

Country Participation: An Overview for Interested Investigators Country Participation: An Overview for Interested Investigators 1 Introduction This document provides an overview of the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). If you have any

More information

IAASB Exposure Draft, Proposed ISAE 3000 (Revised), Assurance Engagements Other Than Audits or Reviews of Historical Financial Information

IAASB Exposure Draft, Proposed ISAE 3000 (Revised), Assurance Engagements Other Than Audits or Reviews of Historical Financial Information Tel +44 (0) 20 7694 8871 Fax +44 (0) 20 7694 8429 8 Salisbury Square DX 38050 Blackfriars London EC4Y 8BB sylvia.smith@kpmgifrg.com United Kingdom Technical Director International Auditing and Assurance

More information

Blank WHAT S NEW IN ACCREDITATION? APPROPRIATE USE AND THE NEW STANDARDS ECHO HAWAII JANUARY 26, 2017 DISCLOSURES

Blank WHAT S NEW IN ACCREDITATION? APPROPRIATE USE AND THE NEW STANDARDS ECHO HAWAII JANUARY 26, 2017 DISCLOSURES Blank WHAT S NEW IN ACCREDITATION? APPROPRIATE USE AND THE NEW STANDARDS ECHO HAWAII JANUARY 26, 2017 David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division

More information

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE A. 510(k) Number: k063276 B. Purpose for Submission: New device C. Measurand: Urinary Glucose, Blood,

More information

Biological Consulting Services of North Florida, Inc.

Biological Consulting Services of North Florida, Inc. Biological Consulting Services of North Florida, Inc. March 20, 2017 Project Manager 6915 Meade St. Pittsburg, PA 15208 757-817-3897 uriel@rorusinc.com Client ID: Core Filter 1, Core Filter 2, Core Filter

More information